282 related articles for article (PubMed ID: 31417239)
1. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
Karachaliou N; Papadaki C; Lagoudaki E; Trypaki M; Sfakianaki M; Koutsopoulos A; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
PLoS One; 2013; 8(9):e74611. PubMed ID: 24058603
[TBL] [Abstract][Full Text] [Related]
3. Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.
Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
Curr Oncol; 2019 Jun; 26(3):e372-e384. PubMed ID: 31285682
[TBL] [Abstract][Full Text] [Related]
4. Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.
Yang X; Bai F; Xu Y; Chen Y; Chen L
Cell Physiol Biochem; 2017; 43(3):1126-1139. PubMed ID: 28977798
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA expression and clinical outcome of small cell lung cancer.
Lee JH; Voortman J; Dingemans AM; Voeller DM; Pham T; Wang Y; Giaccone G
PLoS One; 2011; 6(6):e21300. PubMed ID: 21731696
[TBL] [Abstract][Full Text] [Related]
6. [A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients].
Pu D; Hou M; Li Z; Zeng X
Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):20-4. PubMed ID: 23327869
[TBL] [Abstract][Full Text] [Related]
7. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
[TBL] [Abstract][Full Text] [Related]
8. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C
Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851
[TBL] [Abstract][Full Text] [Related]
9. The effect of brassinolide, a plant steroid hormone, on drug resistant small-cell lung carcinoma cells.
Sadava D; Kane SE
Biochem Biophys Res Commun; 2017 Nov; 493(1):783-787. PubMed ID: 28847728
[TBL] [Abstract][Full Text] [Related]
10. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
11.
Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
[TBL] [Abstract][Full Text] [Related]
12. Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.
Teicher BA; Silvers T; Selby M; Delosh R; Laudeman J; Ogle C; Reinhart R; Parchment R; Krushkal J; Sonkin D; Rubinstein L; Morris J; Evans D
Cancer Med; 2017 Aug; 6(8):1952-1964. PubMed ID: 28766886
[TBL] [Abstract][Full Text] [Related]
13. Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Han D; Wang G; Sun L; Ren X; Shang W; Xu L; Li S
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28707433
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
Liu ZL; Wang B; Liu JZ; Liu WW
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1076-S1083. PubMed ID: 30539849
[TBL] [Abstract][Full Text] [Related]
16. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
17. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
18. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
19. Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Dean EJ; Cummings J; Roulston A; Berger M; Ranson M; Blackhall F; Dive C
Neoplasia; 2011 Apr; 13(4):339-47. PubMed ID: 21472138
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z
BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
